Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development expense	$ 11,901	$ 20,071
General and administrative	9,053	11,318
Total operating expenses	20,954	31,389
Loss from operations	(20,954)	(31,389)
Other income, net:
Interest and investment income	1,673	9
Sublease income	38
Total other income, net	1,711	9
Net loss	$ (19,243)	$ (31,380)
Net loss per common share - basic	$ (0.54)	$ (0.97)
Net loss per common share - diluted	$ (0.54)	$ (0.97)
Weighted average shares of common stock outstanding - basic	35,351,671	32,316,689
Weighted average shares of common stock outstanding - diluted	35,351,671	32,316,689
Other comprehensive income:
Net unrealized gain on marketable debt securities	$ 696
Other comprehensive income	696
Comprehensive loss	$ (18,547)	$ (31,380)